

OTCQB Certification

I, James Nathanielsz, Chief Executive Officer of Propanc Biopharma Inc. ("the Company"), certify that:

a. The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below (mark the box below that applies with an "X"):

- ☒ Company is registered under Section 12(g) of the Exchange Act
- ☐ Company is relying on Exchange Act Rule 12g3-2(b)
- ☐ Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
- ☐ Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
- ☐ Company is reporting under Section 15(d) of the Exchange Act.
- ☐ Company is reporting under the Alternative Reporting Company Disclosure Guidelines
- ☐ Other (describe) _____

b. The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.

c. The Company Profile displayed on www.otcmarkets.com is current and complete as of [must be latest practicable date] and includes the total shares outstanding, authorized, and in the public float as of that date.

d. Please provide the following information as of the latest practicable date:

i. Number of Beneficial Owners holding at least 100 shares: 1,219 as of 10/28/19

("Beneficial Owner" shall mean any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security.)

ii. Number of shares in the Public Float: 1,272,422 as of 11/6/2019

("Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding, or any Affiliates thereof, or any Immediate Family Members of officers, directors and control persons.)

e. The company is duly organized, validly existing and in good standing under the laws of Delaware in which the Company is organized or does business.

f. Identify any law firm and attorney(s) that acted as the Company's primary legal counsel in preparing its most recent annual report. Include the firm and attorney(s) name if outside counsel, or name and title if internal counsel. (If no attorney assisted in putting together the disclosure, the Company must identify the person or persons who prepared the disclosure and their relationship to the company.) Please also identify any other attorney, if different than the primary legal counsel, that assisted the company during the prior fiscal year on any matter including but not limited to, preparation of disclosure, press releases, consulting services, corporate action or merger assistance, etc.

Primary Legal Counsel

Lucosky Brookman LLP
101 Wood Avenue South
Woodbridge, New Jersey, 08830
Joseph Lucosky Esq.
Seth Brookman Esq.
Scott Linsky Esq.

Former Legal Counsel

Foley Shechter LLP
1359 Broadway, Suite 2001
New York, New York, 10018
Jonathan Shechter, Esq.
Sasha Ablovatskiy, Esq.

g. The following is a complete list of third party providers, including names and addresses, engaged by the Company, its officers, directors or controlling shareholders, during the period from the Company's prior fiscal year end to the date of this OTCQB Certification, to provide investor relations services, public relations services, marketing, brand awareness, consulting, stock promotion, or any other related services to the Company.

Current Third Party Provider

SilvaCap Media
516 SW, 13th Street, Suite 201
Bend, OR 97702
Attn: Ross Silver, Principal

Previous Third Party Providers

Regal Consulting LLC
Attn: Parker Mitchell, Managing Partner

LaVoieHealthScience
Attn: Donna LaVoie, President


h. The following is a complete list of Officers, Directors and Control Persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), including name, address, and number of shares owned. Options and warrants that can be converted into common shares within the next 60 days should be included in the shareholdings listed below. If any of the beneficial shareholders are corporate entities, provide the name and address of the person(s) owning or controlling such corporate entities.

Name	Address (City and State only)	Number of Shares Owned
James Nathanielsz (CEO, Chairman, Director)	Glen Iris, Australia	39,572 options 1 share of Series B preferred stock
Dr Julian Kenyon (CSO, Director)	Hampshire, UK	20,072 options
North Horizon Investments Pty Ltd., James Nathanielsz, Director	Glen Iris, Australia	345 shares of common stock 500,000 shares of Series A preferred stock
Auctus Fund LLC, Lou Posner, Managing Director	Boston, MA	975,000 warrants
Carlo Campiciano	Glen Iris, Australia	0 shares of common stock, warrants, and options

Date: 11/11/2019

Name of Certifying CEO or CFO: James Nathanielsz

Title: CEO

Signature:  JAMES NATHANIELSZ
(Digital Signatures should appear as "/s/ [OFFICER NAME]")